Provider review
Henry Meds Review: Formulation and Evidence
Henry offers several GLP-1 formats. The most important comparison is which preparation your clinician proposes, because evidence for an injection does not automatically establish an oral compound or a microdose plan.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Henry MedsOf Henry Meds’s 1 dated product claim documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Henry is worth comparing when you want a clinician to discuss different treatment formats. Ask for evidence about the actual preparation offered, particularly if convenience leads you toward an oral compound or microdose plan.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Henry Meds
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — The cited offer lists injectable semaglutide from $197 per month. This is an advertised starting figure; the selected term and current written quote determine the amount due.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Henry Meds's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Henry Meds’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“For sustainable, long-term results”
Read on the Henry Meds site, October 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry read October 13, 2026. This study supports the molecule and studied injection, not this provider’s compounded formulation.
Semaglutide has randomized weight-management evidence, but STEP 1 studied a specific injected formulation. This broad claim should not be read as validation of every Henry preparation or a promise that an individual result will persist.2
Dispensing chain
Who actually fills your prescription
Read the full account
Henry’s terms distinguish the platform, clinician and pharmacy. They describe affiliated-pharmacy fulfillment and an option to use another pharmacy, where costs can differ. The terms identify patient-specific 503A compounding; verify the actual pharmacy assigned to the prescription.
Read on the Henry Meds site, October 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No batch report was assessed in the cited treatment-page review. This does not establish that the pharmacy does not test; request the report matching the dispensed lot.
Read on the Henry Meds site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
Confirm treatment availability for your state
Read the full licensing claim
A public treatment listing does not establish eligibility for every state or every patient. Confirm the clinician and dispensing pharmacy for your location.
Read on the Henry Meds site, October 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Public pages distinguish compounded products from FDA-approved medication.
- The terms explain that clinical and pharmacy decisions belong to separate licensed professionals.
- Several formats are described before a consultation.
- An injection study cannot settle the effectiveness of a compounded oral product.
- Starting prices do not establish the full payment or renewal terms.
- The microdose offer requires a separate evidence discussion.
Verdict
The bottom line
Choose on the basis of the prescription, its evidence and the pharmacy that will fill it. A shared ingredient name is an incomplete comparison.
Opens Henry Meds' website. A link is not a recommendation to take anything.
The formulation matters more than the menu
Henry’s public offer includes compounded injectable and oral semaglutide, oral tirzepatide and a semaglutide microdose option. That gives a prospective patient several formats to discuss, but a larger menu does not make the options interchangeable. The review here focuses on semaglutide and the questions raised by those formulation choices. It is an assessment of public information, not a report of receiving treatment. 1
Start the consultation with the problem you want treated and any practical obstacle to care. If needles are the obstacle, ask the clinician to compare evidence for the proposed alternative. Convenience has value, but it is a different question from how much of an ingredient reaches the circulation or what clinical outcomes a finished product has demonstrated.
Full analysis — 3 more sectionsWhat the trial can establish · Microdosing deserves its own conversation · The pharmacy and payment are separate decisions
What the trial can establish
STEP 1 randomized adults with overweight or obesity without diabetes to injected semaglutide or placebo alongside lifestyle intervention. It supports a weight-management effect for the studied intervention. It does not directly test Henry’s compounded tablets, drops or microdose offering. A prescriber should explain that difference rather than treating every appearance of the same molecule as the same evidence. 2
FDA says compounded drugs do not receive its premarket review for safety, effectiveness and quality. The agency recommends discussing medical need and obtaining the prescription from a clinician and a state-licensed pharmacy. This is a product distinction, not proof that a particular patient will have a poor result. 3
Microdosing deserves its own conversation
Henry markets a lower-exposure approach around easier adjustment and tolerability. That is a proposition to discuss with the prescriber. Ask what outcome is expected, how it will be assessed, and which evidence applies to the exact plan. A lower amount alone does not establish a particular balance of benefit and risk, and this page does not provide a regimen. 6
It is useful to agree on a reassessment point before starting: what would count as enough benefit, what would prompt a review, and who should be contacted if the plan is not working? The answers should concern your health and the actual prescription, rather than a promised transformation date.
The pharmacy and payment are separate decisions
Henry’s terms describe a platform connecting patients with independent clinicians and pharmacies. The program terms also show that payment and medication delivery can follow different schedules. Get a written description of the total charge, what supply it covers, subsequent payments and the dispensing pharmacy. A monthly headline is not enough to compare two plans with different terms. 45
If you prefer a different pharmacy, discuss that before paying. The terms allow that possibility but explain that separately obtained medication can have a different cost. Keeping the clinical decision, fulfillment and billing clear helps prevent an apparently simple treatment choice from becoming a surprise at renewal. 4
Questions
Frequently asked questions
Does oral semaglutide mean the same thing as an injection?
No. The route and finished formulation matter. Ask which clinical evidence supports the specific product proposed; an ingredient name alone does not settle that question.
Is the starting price my complete charge?
Not necessarily. Obtain the selected term, total due, delivery schedule and renewal amount in writing.
Does a compounded prescription have FDA approval?
No. Compounded preparations are not FDA-approved finished products, even when an ingredient also appears in an approved medicine.
Compare
Others selling what Henry Meds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Henry Meds is on
Method
How we checked this
Non-product facts last checked October 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Henry Meds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Henry Meds (2026). Current public treatment offer. Henry Meds; accessed October 13, 2026. the Henry Meds site
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH et al.; accessed October 13, 2026. https://pubmed.ncbi.nlm.nih.gov/33567185/
- FDA (2026). Concerns with unapproved GLP-1 drugs. FDA; accessed October 13, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Henry Meds (2026). Terms of service. Henry Meds; accessed October 13, 2026. the Henry Meds site
- Henry Meds (2026). Program terms. Henry Meds; accessed October 13, 2026. the Henry Meds site
- Henry Meds (2026). Compounded GLP-1 microdose. Henry Meds; accessed October 13, 2026. the Henry Meds site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.